Society for Surgery of the Alimentary Tract Annual Meeting
 

 
Back to SSAT Site
Annual Meeting
  Home
  Program and Abstracts
  Ticketed & Highlighted Sessions
  Past & Future Meetings
  Photo Gallery
  Past DDW on Demand
Winter Course
Other Meetings of Interest
 

Back to 2018 Program and Abstracts


T2B INCIDENTAL GALLBLADDER CANCER PATIENTS DERIVE A NEGATIVE IMPACT ON SURVIVAL FROM INDEX CHOLECYSTECTOMY
Eduardo A. Vega*1,2, Eduardo Vinuela2,3, Marcel P. Sanhueza2,3, Cristian Diaz2,3, Nicolas Jarufe3, Jorge Martinez3, Masuyuki Okuno1, Katharina Joechle1, Yun Shin Chun1, Ching-Wei Tzeng1, Jeffrey E. Lee1, Jean-Nicolas Vauthey1, Claudius Conrad1
1Surgical Oncology, MD Anderson Cancer Center, Houston, TX; 2Surgery, Hospital Sotero del Rio, Santiago, RM, Chile; 3Surgery, Pontificie Universidad Catolica de Chile, Santiago, RM, Chile

BACKGROUND: It is presumed that the non-oncological index cholecystectomy (IC) leading to discovery of incidental gallbladder cancer (IGBC) does not significantly impact survival. This study compares the outcome of non-IGBC vs IGBC to identify patients that may have a negative impact from failure of performing upfront radical cholecystectomy,
METHODS: Clinical and pathologic features of non-IGBC and IGBC patients treated with curative intent at two centers (USA and Chile) during 1999-2016 were compared. Patients with T1 and T4 tumors and preoperative jaundice were excluded. T2 IGBC and non-IGBC were stratified by the presence of hepatic side tumor at IC which has been shown to be a predictor of worse survival (AJCC 8th). Predictors of disease-specific survival (DSS) were analyzed.
RESULTS: The study included 196 patients: 151 (77%) with IGBC and 45 (23%) with non-IGBC. Major liver resection, operative mortality, major complication, N+ status and R1 resection were comparable. DSS rate in IGBC vs non-IGBC was 60% vs 50% at 3 years (p=0.064). Further, 118 (78%) IGBC patients and 18 (48%) non-IGBC patients had T2 disease. Eleven (10%) T2b IGBC and 7 (41.2%) T2b non-IGBC patients had tumor at the hepatic side. T2 and T3 IGBC vs non-IGBC had similar survival (T2: DSS rate at 3 years 63% vs 81%, p=0.730; T3: DSS rate at 3 years 29% vs 46%, p=0120). However, T2b IGBC patients had lower DSS rates than T2b non-IGBC (DSS rate at 3 years, 31% vs 85%; p=0.019). Further, T2b IGBC patients DSS was inferior when the time interval between IC and OER is >60 days. (DSS rate at 3 years, 16% vs 85%; p=0.004). In multivariate analysis of T2 patients, predictive factors for poor DSS are hepatic side tumor in IGBC patients (hazard ratio (HR), 3.2; 95% CI, 1.1-9.4; p=0.032) and N1 status (HR, 2.3; 95% CI, 1.2-4.5; p=0.011).
CONCLUSIONS: Patients with T2b IGBC benefit from single operation even when patients are rendered disease free during a follow up oncologic extended resection. Efforts should be made to identify T2 IGBC preoperatively to refer these patients to centers with expertise in oncologic resection for GB cancer.


Back to 2018 Program and Abstracts



© 2018 Society for Surgery of the Alimentary Tract. All Rights Reserved. Read the Privacy Policy.